SEAWOLF THERAPEUTICS Trademark

Trademark Overview

On Thursday, October 21, 2021, a trademark application was filed for SEAWOLF THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the SEAWOLF THERAPEUTICS trademark a serial number of 97085599. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, September 11, 2024. This trademark is owned by Seawolf Therapeutics, Inc.. The SEAWOLF THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of pharmaceuticals
seawolf therapeutics

General Information

Serial Number97085599
Word MarkSEAWOLF THERAPEUTICS
Filing DateThursday, October 21, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, September 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 27, 2022

Trademark Statements

Pseudo MarkSEA WOLF THERAPEUTICS
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesResearch and development of pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, November 7, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSeawolf Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameSeawolf Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94104

Trademark Events

Event DateEvent Description
Monday, October 25, 2021NEW APPLICATION ENTERED
Sunday, November 7, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 23, 2022EXAMINERS AMENDMENT E-MAILED
Thursday, July 28, 2022ASSIGNED TO EXAMINER
Thursday, August 4, 2022NON-FINAL ACTION WRITTEN
Thursday, August 4, 2022NON-FINAL ACTION E-MAILED
Thursday, August 4, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, August 23, 2022EXAMINERS AMENDMENT -WRITTEN
Tuesday, August 23, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, August 23, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, August 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 7, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 27, 2022PUBLISHED FOR OPPOSITION
Tuesday, September 27, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, March 27, 2023SOU EXTENSION 1 GRANTED
Tuesday, November 22, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, March 27, 2023SOU TEAS EXTENSION RECEIVED
Monday, March 27, 2023SOU EXTENSION 1 FILED
Wednesday, March 29, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 23, 2023SOU TEAS EXTENSION RECEIVED
Monday, October 23, 2023SOU EXTENSION 2 GRANTED
Monday, October 23, 2023SOU EXTENSION 2 FILED
Wednesday, October 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 11, 2024SOU TEAS EXTENSION RECEIVED
Thursday, April 11, 2024SOU EXTENSION 3 FILED
Thursday, April 11, 2024SOU EXTENSION 3 GRANTED
Friday, April 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 11, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, September 11, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 11, 2024SOU EXTENSION 4 GRANTED
Wednesday, September 11, 2024SOU EXTENSION 4 FILED

Related Keywords

therapeutics seawolf pharmaceuticals development research